Regulatory Guidelines

FDA Drug Master File (DMF) Submission Guidelines for Regulatory Compliance

Posted on digi By digi

A DMF is a voluntary submission to the FDA containing detailed, confidential information about the manufacture and control of a drug component. While not required by law or regulation, a DMF is a critical resource during the evaluation of Investigational New Drug (IND), New Drug Application (NDA), Abbreviated New Drug Application (ANDA), or other regulatory submissions when a third party holds proprietary data.
Click to read the full article.

Regulatory Guidelines, U.S. FDA Regulations

EMA Guidance on Good Clinical Practice (GCP): Ensuring Ethical and Compliant Trials in Europe

Posted on digi By digi

Good Clinical Practice is an international quality standard for the design, conduct, performance, monitoring, auditing, recording, analysis, and reporting of clinical trials. It ensures the protection of trial subjects and the credibility of trial data. EMA has adopted ICH E6 (R2) GCP as the baseline requirement for all EU clinical trials.
Click to read the full article.

EMA (European Medicines Agency) Guidelines, Regulatory Guidelines

FDA Clinical Hold Criteria and Procedures: A Detailed Guide for Regulatory Compliance

Posted on digi By digi

A clinical hold is a regulatory mechanism used by the FDA to ensure the safety of human subjects and the integrity of clinical trials. It can be applied during IND review or at any point during the trial lifecycle. The hold may affect all or specific parts of the study and remains in effect until lifted by the FDA.
Click to read the full article.

Regulatory Guidelines, U.S. FDA Regulations

Orphan Designation Criteria under EMA: A Regulatory Guide for Rare Disease Drug Development

Posted on digi By digi

Orphan designation is a status granted by EMA to medicinal products intended for the diagnosis, prevention, or treatment of life-threatening or chronically debilitating rare conditions. It is designed to encourage investment in areas with unmet medical needs and small patient populations.
Click to read the full article.

EMA (European Medicines Agency) Guidelines, Regulatory Guidelines

TGA Guidelines for Clinical Trials and Drug Approvals in Australia: A Complete Overview

Posted on digi By digi

Operating under the Department of Health, the TGA ensures that therapeutic goods supplied in Australia meet rigorous standards of safety, efficacy, and quality. Australia offers a supportive environment for clinical research, bolstered by efficient regulatory frameworks like the Clinical Trial Notification (CTN) and Clinical Trial Approval (CTA) schemes, along with expedited pathways for promising therapies.
Click to read the full article.

Regulatory Guidelines, TGA (Australia) Guidelines

MHRA Guidelines for Clinical Trials and Drug Approvals in the UK: A Complete Overview

Posted on digi By digi

The MHRA regulates the development, licensing, and monitoring of medicines and medical devices within the UK. After the UK’s exit from the European Union, the MHRA has assumed full responsibility for decisions that were previously made in conjunction with the EMA. The agency now operates autonomous pathways designed to maintain high regulatory standards while supporting rapid access to new treatments.
Click to read the full article.

MHRA (UK) Guidelines, Regulatory Guidelines